A randomized, placebo-controlled phase 3 study of plozasiran in patients with familial chylomicronemia syndrome: PALISADE - 1 year open label extension
                              
 
                                  Event:
                                  
                                    ESC Congress 2025
                                  
 
                                  Topic:
                                  
                                    Cardiovascular Disease in Primary Care
                                  
 
                                  Session:
                                  
                                    Cardiovascular disease in primary care